Neues zu Diagnostik und Therapie des idiopathischen Parkinson-Syndroms

In Deutschland leben mindestens 300 000 Menschen mit einem idiopathischen Parkinson-Syndrom. Aufgrund des demografischen Wandels ist mit einer stetig steigenden Zahl Betroffener zu rechnen. In diesem Beitrag werden die evidenzbasierte Diagnostik und Therapie des idiopathischen Parkinson-Syndroms dargestellt. Insbesondere soll ein Überblick über die neuen Erkenntnisse und Entwicklungen der letzten Jahre gegeben werden.

Schlüsselwörter

idiopathisches Parkinson-Syndrom - Bewegungsstörung - neurodegenerative Erkrankung - L-Dopa - tiefe Hirnstimulation

• Literatur

• 1 Postuma RB, Berg D, Stern M. et al. MDS clinical diagnostic criteria for Parkinsonʼs disease. Mov Disord 2015; 30: 1591-1601
• 2 Deutsche Gesellschaft für Neurologie – DGN. S3-Leitlinie Idiopathisches Parkinson-Syndrom. In: Leitlinien für Diagnostik und Therapie in der Neurologie. DGN. 2016. Im Internet: https://www.awmf.org/leitlinien/detail/ll/030-010.html Stand: 28.12.2018
• 3 Danel SE, Lees AJ. Parkinsonʼs Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993; 39: 165-172
• 4 Pavese N, Tai YF. Nigrosome imaging and neuromelanin sensitive mri in diagnostic evaluation of Parkinsonism. Mov Disord Clin Pract 2018; 5: 131-140
• 5 Tripathi M, Dhawan V, Peng S. et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 2013; 55: 483-492
• 6 Domingo A, Klein C. Genetics of Parkinson Disease. Handb Clin Neurol 2018; 147: 211-227 doi:10.1016/B978-0-444-63233-3.00014-2
• 7 Berg D, Postuma RB, Adler CH. et al. MDS research criteria for prodromal Parkinsonʼs disease. Mov Disord 2015; 30: 1600-1611
• 8 Fereshtehnejad SM, Romenets SR, Anang JBM. et al. New clinical subtypes of Parkinson disease and their longitudinal progression. JAMA Neurol 2015; 72: 863-873
• 9 Seppi K, Weintraub D, Coelho M. et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinsonʼs disease. Mov Disord 2011; 26 (Suppl. 03) S42-S80
• 10 Fox SH, Katzenschlager R, Lim SY. et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinsonʼs disease. Mov Disord 2018; 33: 1248-1266
• 11 Weintraub D, David AS, Evans AH. et al. Clinical spectrum of impulse control disorders in Parkinsonʼs disease. Mov Disord 2015; 30: 121-127
• 12 Fahn S. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinsonʼs disease?. J Neurol 2005; 252 (Suppl. 04) IV37-IV42
• 13 Ferreira JJ, Lees A, Rocha JF. et al. Opicapone as an adjunct to levodopa in patients with Parkinsonʼs disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial. Lancet Neurol 2016; 15: 154-165
• 14 Schapira AHV, Fox SH, Hauser RA. et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 2017; 74: 216-224
• 15 [No authors listed] Deep brain stimulation for Parkinsonʼs disease with early motor complications. JAMA 2014; 311: 1686-1687
• 16 Antonini A, Moro E, Godeiro C. et al. Medical and surgical management of advanced Parkinsonʼs disease. Mov Disord 2018; 33: 900-908
• 17 Vasconcellos LFR, Pereira JS. Parkinsonʼs disease dementia: Diagnostic criteria and risk factor review. J Clin Exp Neuropsychol 2015; 37: 988-993
• 18 Mathis V M, Muoio BM, Andreason P. et al. The US Food and Drug Administrationʼs perspective on the new antipsychotic pimavanserin. J Clin Psychiat 2017; 78: 668-673
• 19 Henderson EJ, Lord SR, Brodie MA. et al. Rivastigmine for gait stability in patients with Parkinsonʼs disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 249-258
• 20 Tomlinson CL, Patel S, Meek C. et al. Physiotherapy versus placebo or no intervention in Parkinsonʼs disease. Cochrane Database Syst Rev 2013; (09) CD002817
• 21 Da Silva FC, Iop RDR, De Oliveira LC. et al. Effects of physical exercise programs on cognitive function in Parkinsonʼs disease patients: A systematic review of randomized controlled trials of the last 10 years. PLoS One 2018; 13: e0193113 doi:10.1371/journal.pone.0193113